– USA, CA – Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today that the company’s board of directors has appointed Dr. Sunil Agarwal, M.D., Chief Medical Officer and Senior Vice President at Ultragenyx Pharmaceutical Inc., as an independent director.
“Sunil, a seasoned pharmaceutical executive, is a welcome addition to the Calithera Board of Directors as we advance our pipeline through clinical development,” said Susan Molineaux, Ph.D., President and Chief Executive Officer. “Sunil’s experience and proven track record of success will be a tremendous asset to Calithera.”
Dr. Agarwal commented, “I am honored to join Calithera’s Board of Directors at this exciting time as they advance their novel, first in class, tumor metabolism and immuno-oncology anti-cancer agents.”
Dr. Agarwal is currently Senior Vice President and Chief Medical Officer at Ultragenyx where he is responsible for leading the company’s clinical development. Prior to Ultragenyx, Dr. Agarwal served in various leadership capacities at Genentech for 11 years. Most recently he held the position of Senior Vice President and Global Head of Clinical Development for OMNI (Ophthalmology, Metabolism, Neurosciences, Immunology and Infectious Diseases), and was involved in the development oversight of multiple molecules including RITUXAN®, ACTEMRA®, XOLAIR ®, LUCENTIS®, lebrikizumab, and ocrelizumab. Before joining Genentech, Dr. Agarwal was at MedImmune and Guilford Pharmaceuticals where he worked in both development and medical affairs. Dr. Agarwal obtained his B.S. in Neuro-Biology at Cornell University and then earned his M.D. from Tufts University School of Medicine.
About Calithera
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. Calithera is headquartered in South San Francisco.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
